JP2004537498A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004537498A5 JP2004537498A5 JP2002544008A JP2002544008A JP2004537498A5 JP 2004537498 A5 JP2004537498 A5 JP 2004537498A5 JP 2002544008 A JP2002544008 A JP 2002544008A JP 2002544008 A JP2002544008 A JP 2002544008A JP 2004537498 A5 JP2004537498 A5 JP 2004537498A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- compound
- composition
- embedded image
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 13
- 238000000034 method Methods 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 208000031481 Pathologic Constriction Diseases 0.000 description 8
- 208000037804 stenosis Diseases 0.000 description 8
- 230000036262 stenosis Effects 0.000 description 8
- 150000003904 phospholipids Chemical class 0.000 description 5
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 4
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 4
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 4
- 208000018262 Peripheral vascular disease Diseases 0.000 description 4
- 208000026106 cerebrovascular disease Diseases 0.000 description 4
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 4
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 4
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 4
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 4
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 4
- 150000003905 phosphatidylinositols Chemical class 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 125000000524 functional group Chemical group 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical group 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940035676 analgesics Drugs 0.000 description 2
- 239000000730 antalgic agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 229960001334 corticosteroids Drugs 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000004665 fatty acids Chemical group 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- RKIDALSACBQVTN-HHHXNRCGSA-N 1-O-palmitoyl-2-O-(5-oxovaleryl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCC=O)COP([O-])(=O)OCC[N+](C)(C)C RKIDALSACBQVTN-HHHXNRCGSA-N 0.000 description 1
- XUDOZULIAWNMIU-UHFFFAOYSA-N delta-hexenoic acid Chemical compound OC(=O)CCCC=C XUDOZULIAWNMIU-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25257400P | 2000-11-24 | 2000-11-24 | |
| PCT/IL2001/001080 WO2002041827A2 (en) | 2000-11-24 | 2001-11-22 | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008151301A Division JP5001906B2 (ja) | 2000-11-24 | 2008-06-10 | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を含有する組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004537498A JP2004537498A (ja) | 2004-12-16 |
| JP2004537498A5 true JP2004537498A5 (https=) | 2006-01-05 |
| JP4162486B2 JP4162486B2 (ja) | 2008-10-08 |
Family
ID=22956589
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002544008A Expired - Lifetime JP4162486B2 (ja) | 2000-11-24 | 2001-11-22 | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を用いる方法およびそのような酸化型リン脂質を含有する組成物 |
| JP2008151301A Expired - Lifetime JP5001906B2 (ja) | 2000-11-24 | 2008-06-10 | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を含有する組成物 |
| JP2012060309A Pending JP2012149075A (ja) | 2000-11-24 | 2012-03-16 | 酸化型リン脂質の合成方法、及びアテローム性動脈硬化を防止および処置するための医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008151301A Expired - Lifetime JP5001906B2 (ja) | 2000-11-24 | 2008-06-10 | アテローム性動脈硬化を防止および処置するための規定された酸化型リン脂質を含有する組成物 |
| JP2012060309A Pending JP2012149075A (ja) | 2000-11-24 | 2012-03-16 | 酸化型リン脂質の合成方法、及びアテローム性動脈硬化を防止および処置するための医薬組成物 |
Country Status (9)
| Country | Link |
|---|---|
| EP (2) | EP1341543A4 (https=) |
| JP (3) | JP4162486B2 (https=) |
| KR (1) | KR100865142B1 (https=) |
| CN (1) | CN100577174C (https=) |
| AU (2) | AU2002218461B2 (https=) |
| CA (1) | CA2429817C (https=) |
| IL (1) | IL156015A0 (https=) |
| MX (1) | MXPA03004517A (https=) |
| WO (1) | WO2002041827A2 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| US6838452B2 (en) * | 2000-11-24 | 2005-01-04 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
| AU2003243806A1 (en) * | 2002-07-15 | 2004-02-02 | Bernd Binder | Lipid oxidation products for inhibiting inflammation |
| AU2007200090B2 (en) * | 2004-07-09 | 2011-09-22 | Vascular Biogenics Ltd. | Improved Process for the Preparation of Oxidized Phospholipids |
| PL1773352T3 (pl) * | 2004-07-09 | 2014-04-30 | Vascular Biogenics Ltd | Ulepszony sposób wytwarzania utlenionych fosfolipidów |
| US7807847B2 (en) | 2004-07-09 | 2010-10-05 | Vascular Biogenics Ltd. | Process for the preparation of oxidized phospholipids |
| US8569529B2 (en) | 2007-01-09 | 2013-10-29 | Vascular Biogenics Ltd. | High-purity phospholipids |
| US9006217B2 (en) | 2007-01-09 | 2015-04-14 | Vascular Biogenics Ltd. | High-purity phospholipids |
| WO2009116750A2 (ko) * | 2008-03-17 | 2009-09-24 | 이화여자대학교 산학협력단 | 혈관 재협착방지 스텐트 코팅용 조성물 및 이를 이용해 제조된 스텐트 |
| CA2735578C (en) | 2008-08-12 | 2018-10-23 | Zinfandel Pharmaceuticals, Inc. | Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| EP2348864A4 (en) | 2008-10-08 | 2013-07-31 | Vascular Biogenics Ltd | OXIDIZED THIOPHOSPHOLIPID COMPOUNDS AND USES THEREOF |
| EP2826370A3 (en) * | 2008-11-06 | 2015-04-08 | Vascular Biogenics Ltd. | Oxidized lipid compounds and uses thereof |
| JP2013516457A (ja) * | 2010-01-05 | 2013-05-13 | バスキュラー バイオジェニックス リミテッド | Ｖｂ−２０１を用いた併用治療法 |
| EA201391017A1 (ru) | 2011-01-10 | 2014-04-30 | Зинфандел Фармасьютикалз, Инк. | Способы и готовые лекарственные формы для лечения болезни альцгеймера |
| CA2847218C (en) | 2011-09-01 | 2018-02-27 | Vascular Biogenics Ltd. | Formulations and dosage forms of oxidized phospholipids |
| CA2876177C (en) * | 2012-06-11 | 2022-06-14 | The Cleveland Clinic Foundation | Treatment and prevention of cardiovascular disease and thrombosis |
| EP3223824B1 (en) | 2014-11-26 | 2021-01-06 | Vascular Biogenics Ltd. | Oxidized lipids and treatment or prevention of fibrosis |
| US9771385B2 (en) | 2014-11-26 | 2017-09-26 | Vascular Biogenics Ltd. | Oxidized lipids |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| CH642665A5 (en) | 1979-02-08 | 1984-04-30 | Rudolf Berchtold | Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides |
| US4329302A (en) * | 1980-06-27 | 1982-05-11 | Board Of Regents, The University Of Texas System | Synthetic phosphoglycerides possessing platelet activating properties |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| DE3307925A1 (de) * | 1983-03-05 | 1984-09-06 | A. Nattermann & Cie GmbH, 5000 Köln | Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US4614796A (en) * | 1983-03-25 | 1986-09-30 | Nippon Shinyaku Co., Ltd. | Liposome and method of manufacture therefor |
| JPS60100544A (ja) * | 1983-11-08 | 1985-06-04 | Ono Pharmaceut Co Ltd | 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤 |
| JPS60104066A (ja) * | 1983-11-10 | 1985-06-08 | Ono Pharmaceut Co Ltd | グリセリン誘導体 |
| US5869534A (en) | 1992-05-21 | 1999-02-09 | The Picower Institute For Medical Research | Glycosylation of lipids and lipid-containing particles, and diagnostic and therapeutic methods and materials derived therefrom |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4827011A (en) * | 1984-12-10 | 1989-05-02 | American Cyanamid Company | Antihypertensive phosphate derivatives |
| EP0225129B1 (en) | 1985-11-29 | 1989-05-24 | Takeda Chemical Industries, Ltd. | Phospholipid derivatives, their production and use |
| WO1987005904A1 (en) * | 1986-03-24 | 1987-10-08 | The University Of Sydney | Antigenic analogues of platelet activating factor (paf) |
| JPS6354386A (ja) * | 1986-08-26 | 1988-03-08 | Takeda Chem Ind Ltd | リン脂質およびその用途 |
| JPH01258691A (ja) * | 1988-04-06 | 1989-10-16 | Nippon Oil & Fats Co Ltd | リン脂質誘導体及びその製造方法 |
| ES2019552A6 (es) * | 1990-04-11 | 1991-06-16 | Menarini Lab | Procedimiento para la preparacion de glicerofosfolipidos. |
| US5561052A (en) | 1992-06-18 | 1996-10-01 | Koike; Katsumasa | Process for detecting oxidized lipids and process for forming oxidized lipids |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US5807884A (en) | 1992-10-30 | 1998-09-15 | Emory University | Treatment for atherosclerosis and other cardiovascular and inflammatory diseases |
| FR2714382B1 (fr) | 1993-12-27 | 1996-02-02 | Roussel Uclaf | Phospholipides vecteur de molécule active, leur préparation et leur utilisation dans des compositions cosmétiques ou dermatologiques. |
| DE69533545T2 (de) | 1994-01-31 | 2006-01-05 | Institute Of Cancer Research Royal Cancer Hospital | Faltende proteine |
| AU1751795A (en) * | 1994-03-04 | 1995-09-18 | University Of British Columbia, The | Liposome compositions and methods for the treatment of atherosclerosis |
| JP3364313B2 (ja) * | 1994-03-22 | 2003-01-08 | 株式会社トクヤマ | ポルフィリン／インジウム錯体及び陰イオン感応膜 |
| US5660855A (en) * | 1995-02-10 | 1997-08-26 | California Institute Of Technology | Lipid constructs for targeting to vascular smooth muscle tissue |
| US6156500A (en) | 1995-02-10 | 2000-12-05 | Millennium Pharmaceuticals, Inc. | Methods for the treatment and diagnosis of cardiovascular disease |
| US6261597B1 (en) | 1995-08-31 | 2001-07-17 | Seymour J. Kurtz | Method for treating periodontal disease |
| US6034102A (en) | 1996-11-15 | 2000-03-07 | Pfizer Inc | Atherosclerosis treatment |
| US6114395A (en) | 1996-11-15 | 2000-09-05 | Pfizer Inc. | Method of treating atherosclerosis |
| US6096291A (en) | 1996-12-27 | 2000-08-01 | Biovector Therapeutics, S.A. | Mucosal administration of substances to mammals |
| US5935577A (en) | 1998-01-23 | 1999-08-10 | Autoimmune Inc. | Treatment of autoimmune disease using tolerization in combination with methotrexate |
| US5945308A (en) | 1998-04-03 | 1999-08-31 | Incyte Pharmaceuticals, Inc. | Human oxidized LDL receptor |
| US6309888B1 (en) | 1998-09-04 | 2001-10-30 | Leuven Research & Development Vzw | Detection and determination of the stages of coronary artery disease |
| US6701176B1 (en) | 1998-11-04 | 2004-03-02 | Johns Hopkins University School Of Medicine | Magnetic-resonance-guided imaging, electrophysiology, and ablation |
| WO2002041827A2 (en) * | 2000-11-24 | 2002-05-30 | Vascular Biogenics Ltd. | Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis |
-
2001
- 2001-11-22 WO PCT/IL2001/001080 patent/WO2002041827A2/en not_active Ceased
- 2001-11-22 IL IL15601501A patent/IL156015A0/xx active IP Right Grant
- 2001-11-22 CA CA2429817A patent/CA2429817C/en not_active Expired - Fee Related
- 2001-11-22 CN CN01822215A patent/CN100577174C/zh not_active Expired - Lifetime
- 2001-11-22 EP EP01997274A patent/EP1341543A4/en not_active Withdrawn
- 2001-11-22 MX MXPA03004517A patent/MXPA03004517A/es active IP Right Grant
- 2001-11-22 AU AU2002218461A patent/AU2002218461B2/en not_active Ceased
- 2001-11-22 JP JP2002544008A patent/JP4162486B2/ja not_active Expired - Lifetime
- 2001-11-22 AU AU1846102A patent/AU1846102A/xx active Pending
- 2001-11-22 EP EP11189562A patent/EP2425841A1/en not_active Withdrawn
- 2001-11-22 KR KR1020037006991A patent/KR100865142B1/ko not_active Expired - Fee Related
-
2008
- 2008-06-10 JP JP2008151301A patent/JP5001906B2/ja not_active Expired - Lifetime
-
2012
- 2012-03-16 JP JP2012060309A patent/JP2012149075A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004537498A5 (https=) | ||
| CN1090479C (zh) | 一种胆固醇生物合成抑制剂与一种β-内酰胺胆固醇吸收抑制剂的联合 | |
| JP2003530318A5 (https=) | ||
| JP2024504932A5 (https=) | ||
| DK2736510T3 (en) | METHYLPHENIDATE PRODRUGS, PROCEDURES FOR PREPARING IT AND USING THE SAME | |
| JP5752599B2 (ja) | 酸化脂質化合物およびその使用 | |
| JP2004521894A5 (https=) | ||
| JP2002518502A5 (https=) | ||
| JP2002543121A5 (https=) | ||
| CN1446093A (zh) | 两性离子型磷脂和双膦酸酯的独特组合物及其作为降低肠胃毒性的双膦酸酯释放系统的应用 | |
| RU99120178A (ru) | Соединения для ингибирования секреции желудочной кислоты | |
| EP2792353A3 (en) | Compounds and methods for delivery of prostacyclin analogs | |
| JP2004508410A5 (https=) | ||
| JPH0313203B2 (https=) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| EP0546796A1 (en) | Treatment of Atherosclerosis | |
| JP2004517843A5 (https=) | ||
| CN100584851C (zh) | 仲醇磷酸盐 | |
| JP2002542298A5 (https=) | ||
| JP2001520994A5 (https=) | ||
| CN1139432A (zh) | 一种hiv蛋白酶抑制剂前药 | |
| JP2025118775A5 (https=) | ||
| US5478819A (en) | Phospholipid composition and use thereof | |
| JPH1036365A5 (https=) | ||
| JP2001519413A5 (https=) |